Replimune Group (NASDAQ:REPL – Get Free Report) had its price objective upped by equities research analysts at Piper Sandler from $14.00 to $27.00 in a report issued on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler‘s price target would suggest a potential upside of 23.34% from the company’s previous close.
Several other equities research analysts have also recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Replimune Group in a research report on Wednesday, November 4th. Leerink Partners raised their price objective on shares of Replimune Group from $19.00 to $31.00 and gave the company an “outperform” rating in a research note on Thursday, October 29th. Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price for the company in a report on Friday, August 7th. JPMorgan Chase & Co. upped their target price on shares of Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, August 26th. Finally, Wall Street Zen upgraded shares of Replimune Group from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $18.17.
Check Out Our Latest Research Report on REPL
Replimune Group Price Performance
Shares of REPL stock opened at $21.89 on Monday. The firm has a market cap of $2.08 billion, a price-to-earnings ratio of -7.85 and a beta of 0.93. Replimune Group has a 12 month low of $1.50 and a 12 month high of $23.54. The company has a quick ratio of 6.90, a current ratio of 7.11 and a debt-to-equity ratio of 0.59. The stock has a 50-day moving average price of $14.76 and a 200 day moving average price of $10.04.
Replimune Group (NASDAQ:REPL – Get Free Report) last released its earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.24. Research analysts expect that Replimune Group will post -2.40 EPS for the current year.
Insider Transactions at Replimune Group
In other Replimune Group news, Director Kapil Dhingra sold 21,500 shares of the business’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $19.00, for a total value of $408,500.00. Following the completion of the transaction, the director directly owned 21,669 shares of the company’s stock, valued at approximately $411,711. The trade was a 49.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Joseph P. Slattery sold 5,200 shares of the stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $21.80, for a total value of $113,360.00. Following the completion of the sale, the director owned 1,467 shares of the company’s stock, valued at $31,980.60. This trade represents a 78.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 5.40% of the stock is currently owned by insiders.
Institutional Trading of Replimune Group
Large investors have recently bought and sold shares of the business. Quantinno Capital Management LP raised its holdings in shares of Replimune Group by 782.7% during the first quarter. Quantinno Capital Management LP now owns 108,477 shares of the company’s stock worth $830,000 after acquiring an additional 96,188 shares during the period. Montanova Capital LLC boosted its stake in Replimune Group by 4.0% in the 2nd quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock worth $48,595,000 after purchasing an additional 168,000 shares during the period. Seven Fleet Capital Management LP acquired a new position in Replimune Group in the 1st quarter worth $921,000. Squarepoint Ops LLC bought a new position in Replimune Group during the 2nd quarter worth about $1,454,000. Finally, Deutsche Bank AG bought a new position in Replimune Group during the 2nd quarter worth about $857,000. 92.53% of the stock is owned by institutional investors.
Replimune Group Company Profile
Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.
Featured Stories
- Five stocks we like better than Replimune Group
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
